Hong Kong's New Competition Law Could Have Impact On Drug Firms Around The World
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Hong Kong's Legislative Council has begun reviewing a new competition bill that, depending on the contours of the law that is ultimately approved, could have a significant impact on the healthcare sector and life science-based enterprises, according to two lawyers who have closely studied the bill